Orally administered sodium nitrite prevents the increased α-1 adrenergic vasoconstriction induced by hypertension and promotes the S-nitrosylation of calcium/calmodulin-dependent protein kinase II

• Published in: Biochemical pharmacology Vol. 212; p. 115571
• Main Authors: Oliveira-Paula, Gustavo H., I. M. Batista, Rose, Stransky, Stephanie, Tella, Sandra C., Ferreira, Graziele C., Portella, Rafael L., Pinheiro, Lucas C., Damacena-Angelis, Celio, Riascos-Bernal, Dario F., Sidoli, Simone, Sibinga, Nicholas, Tanus-Santos, Jose E.
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.06.2023
• Subjects: Adrenergic Agents - pharmacology; Adrenergic Agents - therapeutic use; Animals; Antihypertensive Agents - pharmacology; Antihypertensive Agents - therapeutic use; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; CaMKII; Hypertension; Hypertension - chemically induced; Hypertension - drug therapy; Hypertension - prevention & control; Nitrite; Phenylephrine - pharmacology; Rats; Receptors, Adrenergic - therapeutic use; Receptors, Adrenergic, alpha-1 - metabolism; S-nitrosylation; Sodium Nitrite; Vascular smooth muscle cells; Vasoconstriction; α-1 adrenergic receptor; Hypertension; SBP; NO; RXNO; DOCA; PKC; Nitrite; GSNO; CaMKIIγ; DMEM; CaMKII; PE; SNO-RAC; FBS; α-1 adrenergic receptor; S-nitrosylation; VSMC; 2K1C; SHR; Vascular smooth muscle cells; Emax; SNO-CaMKIIγ
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2023.115571

[Display omitted] The unsatisfactory rates of adequate blood pressure control among patients receiving antihypertensive treatment calls for new therapeutic strategies to treat hypertension. Several studies have shown that oral sodium nitrite exerts significant antihypertensive effects, but the mechanisms underlying these effects remain unclear. While these mechanisms may involve nitrite-derived S-nitrosothiols, their implication in important alterations associated with hypertension, such as aberrant α1-adrenergic vasoconstriction, has not yet been investigated. Here, we examined the effects of oral nitrite treatment on vascular responses to the α1-adrenergic agonist phenylephrine in two-kidney, one clip (2K1C) hypertensive rats and investigated the potential underlying mechanisms. Our results show that treatment with oral sodium nitrite decreases blood pressure and prevents the increased α1-adrenergic vasoconstriction in 2K1C hypertensive rats. Interestingly, we found that these effects require vascular protein S-nitrosylation, and to investigate the specific S-nitrosylated proteins we performed an unbiased nitrosoproteomic analysis of vascular smooth muscle cells (VSMCs) treated with the nitrosylating compound S-nitrosoglutathione (GSNO). This analysis revealed that GSNO markedly increases the nitrosylation of calcium/calmodulin-dependent protein kinase II γ (CaMKIIγ), a multifunctional protein that mediates the α1-adrenergic receptor signaling. This result was associated with reduced α1-adrenergic receptor-mediated CaMKIIγ activity in VSMCs. We further tested the relevance of these findings in vivo and found that treatment with oral nitrite increases CaMKIIγ S-nitrosylation and blunts the increased CaMKIIγ activity induced by phenylephrine in rat aortas. Collectively, these results are consistent with the idea that oral sodium nitrite treatment increases vascular protein S-nitrosylation, including CaMKIIγ as a target, which may ultimately prevent the increased α1-adrenergic vasoconstriction induced by hypertension. These mechanisms may help to explain the antihypertensive effects of oral nitrite and hold potential implications in the therapy of hypertension and other cardiovascular diseases associated with abnormal α1-adrenergic vasoconstriction.